We have generated mice with markedly elevated plasma levels of human low density lipoprotein (LDL) and reduced plasma levels of high density lipoprotein. 
Atherosclerosis is a complex, multifactorial process whose analysis has been greatly facilitated by the development of genetically modified mice. ApoE-deficient mice (apoE Ϫ͞Ϫ ) are currently the most widely utilized animal model for the study of atherosclerosis (1, 2) . ApoE Ϫ͞Ϫ mice maintained on a low fat, mouse-chow diet have dramatically elevated plasma levels of cholesterol, and they develop extensive atherosclerotic lesions widely distributed throughout the aorta (1) (2) (3) (4) (5) . The effect of other genes on the development of atherosclerosis has been examined by crossing the apoE Ϫ͞Ϫ mice with other genetically manipulated animals (6) (7) (8) .
In wild-type mice, Ϸ90% of plasma cholesterol circulates in high density lipoproteins (HDL). In ApoE Ϫ͞Ϫ mice, the cholesterol is predominantly in the very low density lipoproteins (VLDL) and in the intermediate density lipoprotein fractions (IDL) (1, 2) . The most common lipoprotein pattern in humans with coronary artery disease consists of elevated plasma levels of low density lipoprotein cholesterol (LDL-C) and decreased HDL-C, with or without increases in plasma IDL and VLDL. The strong association between plasma LDL-C and coronary artery disease in humans is reflected in the clinical outcome of subjects with familial hypercholesterolemia (9) . Familial hypercholesterolemia is an autosomal dominant disorder caused by mutations in the LDL receptor (LDLR) gene, which encodes a cell surface receptor that binds and internalizes plasma LDL. Individuals heterozygous for a mutation at the LDLR locus have 2-to 3-fold elevated levels of LDL-C and a striking increase in the incidence of premature coronary artery disease (9) . Familial hypercholesterolemia homozygotes [LDLR Ϫ͞Ϫ ] have 6-to 10-fold elevations in LDL and develop diffuse atherosclerotic lesions in childhood.
Plasma levels of LDL are increased Ϸ2-to 3-fold in mice homozygous for an inactivated LDLR gene [LDLR Ϫ͞Ϫ ] (10), but they do not develop significant atherosclerotic lesions unless they consume a high fat, high cholesterol diet (11) . The relative resistance of mice to LDLR deficiency has been attributed to the production of apoB-48, in addition to apoB-100 in the liver. Whereas human liver produces only apoB-100, mice produce both apoB-100 and its truncated variant, apoB-48. Lipoprotein containing apoB-48 can be cleared from the plasma by other receptors in addition to the LDLR, and hence mouse lipoproteins do not rise as high as human lipoproteins when LDL receptors are deficient. Mice have been generated that produce human apoB-100 in the liver (12, 13) . These animals show a modest increase in LDL cholesterol but again develop atherosclerosis only after ingestion of a high cholesterol, high fat diet (14, 15) . The atherogenic diet required to produce vascular lesions in the LDLR Ϫ͞Ϫ and apoB-100 transgenic mice significantly alters the plasma lipid profile and may affect the vessel wall independently of plasma lipid elevations (16) . These features have limited the usefulness of the LDLR Ϫ͞Ϫ and apoB-100 transgenic mice for atherosclerosis studies.
High plasma levels of lipoprotein(a) [(Lp(a)], another LDLcontaining lipoprotein, also are associated with atherosclerosis in man (17) , but controversy persists regarding the atherogenicity of apo(a) in mice. Apo(a), the large glycoprotein that is attached covalently to the apoB-100 of LDL in the Lp(a) particle, is not found in the plasma of most mammals, including mice. Mice expressing a human apo(a) transgene [Tg(apoa ϩ͞Ϫ )] have apo(a) in their plasma, but it is not disulfide-linked to mouse apoB-100 (18); these mice do not develop vascular lesions on a low fat diet (19) . Fat-fed apo(a) transgenic mice exhibited a significantly higher mean lesion area of fatty lesions in the aortic root than wild-type mice in some (15, (19) (20) (21) , but not all (22) , studies. A possible explanation for the conflicting results of these studies is that expression of apo(a) alone in the mouse is only marginally atherogenic. The amount of lipid staining in Tg(apoa ϩ͞Ϫ ) mice is modest compared with that seen in chow-fed apoE Ϫ͞Ϫ mice (1) (2) (3) (4) (5) or in fat-fed LDLR Ϫ͞Ϫ (11) or Tg(apoB ϩ͞ϩ ) mice (14, 15) . Moreover, the relevance of the increase in aortic lipid staining in the apo(a) transgenic mice is questionable because apo(a) does not form a covalent linkage with mouse apoB-100 (18) . If human apoB-100 is coexpressed with human apo(a) in the mouse, the apo(a) circulates bound to human apoB-100 as authentic Lp(a) (12, 13) . The amount of aortic lipid-staining in these Tg(apoB ϩ͞Ϫ );Tg(apoa ϩ͞Ϫ ) mice is not significantly higher than in mice expressing only the human apoB-100 transgene (15, 22) . Perhaps Lp(a) does not induce more atherosclerosis because the level of plasma LDL is not high enough to promote lesion development. In humans, the atherogenicity of Lp(a) appears to be enhanced in individuals with elevated plasma levels of LDL (23) .
In the current study, we have constructed LDLR Ϫ͞Ϫ mice that express a human apoB-100 transgene [Tg(apoB ϩ͞ϩ )] with or without coexpression of apo(a) [Tg(apoa ϩ͞Ϫ )]. These mice have very high plasma levels of LDL and develop large atherosclerotic lesions on a low fat diet.
MATERIALS AND METHODS

Mice. LDLR
Ϫ͞Ϫ mice were obtained from Joachim Herz (University of Texas Southwestern Medical Center, Dallas, TX) (10) . These mice, which are hybrids of the 129Sv͞Ev and C57BL͞6 strains, were crossed with C57BL͞6 X SJL hybrid mice expressing a human apoB-100 [Tg(apoB ϩ͞Ϫ )] and apo(a) transgene [Tg(apoa ϩ͞Ϫ )] (12). Genotypes were determined using a PCR-based assay (24) , and plasmas were screened for the presence of human apoB and apo(a) as described (22 ). These mice were hybrids of the 129Sv͞Ev, C57BL͞6, and SJL strains. Ten Tg(apoB ϩ͞ϩ ) mice (five males and five females) in a C57BL͞6 and SJL hybrid background also were included in the study. All of the mice were weaned at 21 days and fed a cholate-free mouse-chow diet containing 6% animal fat and Ͻ0.04% cholesterol (Teklad, mouse͞rat diet 7002; Harlan Teklad, Madison, WI) until they were killed at 6 mo of age. The mice were housed in a conventional, nongerm-free animal facility on 12-h dark͞12-h light cycles and had free access to food and water. Venous blood was drawn by retro-orbital sinus puncture every 8 weeks from 5 to 10 animals of each genotype after the animals had fasted for 4 h.
Analysis of Plasma Lipid and Lipoproteins. Blood samples were collected into citrate-EDTA tubes. Plasma was isolated by centrifugation at 5,000 ϫ g for 10 min and maintained at 4°C, or aliquoted and stored at Ϫ80°C. Plasma cholesterol and triglyceride levels were measured using enzymatic assays (Cholesterol͞HP, Boehringer Mannheim and Triglyceride GPO Trinder, Sigma). Plasma lipoprotein analysis was performed using fast performance liquid chromatography (FPLC); a total of 35 fractions (1.8 ml each) was collected, and the cholesterol content was measured by fluorimetry (10) . In addition, plasma was pooled from 3-4 male mice of each genotype, and the density Ͻ 1.215 g͞liters fraction was subjected to FPLC; the triglycerides and cholesterol were measured in each fraction using the enzymatic assays described above. Plasma levels of human apoB were determined by a nephelometric method (BN II, Boehringer Mannheim) calibrated with World Health Organization-International Federation for Clincial Chemistry reference material (25) , and plasma levels of apo(a) were measured using a double mAb-based enzyme-linked immunoassay (25) . Analyses were performed on plasma samples stored for Ͻ2 mo at Ϫ80°C. The results are expressed as total Lp(a) mass. The plasma apo(a) level can be estimated by multiplying the Lp(a) level by 0.138.
Quantification of Aortic Fatty Lesion Area. Mice were anesthetized by using halothane followed by sodium pentobarbital and then were bled via retro-orbital sinus puncture. A thoracotomy and laparotomy were performed to expose the heart and aorta. A catheter was inserted into the left ventricle of the heart and the right atrium was punctured. Mice were perfused with 20 ml of Dulbecco's PBS until blood had been cleared from the circulation and then with 50 ml of fixative solution [4% (vol͞vol) paraformaldehyde, 7.5% (wt͞vol) sucrose, 430 mM Na 2 EDTA, 10 mM butylated hydroxytoluene, and 1 mM sodium phosphate, pH 7.4]. The aorta was slit open in situ from the arch to the iliac bifurcation along the ventral midline, removed, and pinned out on a wax surface. The lipid-rich lesions were stained with Sudan IV (Fisher Scientific) destained using 80% ethanol, and then stored in fixative (8) . The percentage of aortic surface area that stained with Sudan IV was determined as described (8) .
Immunohistological Studies of Aorta. Aortic root segments were embedded in OCT compound (Sakura Finetek, Torrance, CA), frozen in liquid nitrogen, and sectioned with a cryostat to produce 10-m sections for immunohistochemical evaluation. Cross-sections of the distal aortic sinus and proximal ascending aorta were stained using Oil Red O (26) . Sections were immunostained for apo(a) and apoB as follows. Sections were incubated with 22 g͞ml rabbit polyclonal anti-human apo(a) antibody (Cortex, Irvine, CA) for 1 h or with a rabbit polyclonal anti-human LDL antibody (27) at a 1:250 dilution. This procedure was followed by a 1-h incubation with a secondary antibody, biotinylated goat anti-rabbit IgG (1.5 g͞ml). For apo(a) immunostaining, the tertiary reagent was a streptavidin-alkaline phosphatase conjugate (Histostain DS kit, Zymed), and the quaternary reagent was 5-bromo-4-chloro-3-indolylphosphate͞nitro blue tetrazolium (BCIP-NBT). For apoB, the chromogenic steps included streptavidin-peroxidase and aminoethyl carbazole (Histostain DS kit, Zymed). Chromogen immunostains were photographed with a Nikon Optiphot 2 light microscope.
Statistical Analysis. The plasma levels of cholesterol, triglycerides, apoB and Lp(a), and the percent lesion areas were compared in the groups of mice by using the nonparametric Wilcoxon rank sum test (28) . Correlations between the percent lesion areas and the plasma cholesterol levels were estimated by the Pearson product moment correlation. The statistical significance of the Pearson product moment correlation was assessed using a t test (29) .
RESULTS
Ten male and 10 female mice of the following four genotypes were fed a chow diet from the time of weaning (Ϸ21 days) until 6 mo of age: (Table 1) , and the triglyceride levels were lower in the LDLR Ϫ͞Ϫ mice (147 mg͞dl vs. 119 mg͞dl), although this difference was not statistically significant. The expression of apo(a) in the LDLR Ϫ͞Ϫ mice did not alter the level of plasma cholesterol (311 Ϯ 9 vs. 310 Ϯ 8 mg͞dl) but produced a slight reduction in plasma triglycerides (94 Ϯ 7 vs. 119 Ϯ 8 mg͞dl). The mean plasma level of Lp(a) was 27 mg͞dl, which is almost twice as high as the plasma Lp(a) level in LDLR ϩ͞ϩ mice expressing the same apo(a) transgene (22 To determine the distribution of plasma cholesterol and triglycerides in the lipoproteins of these mice, FPLC analysis was performed on the density Ͻ 1.215 g͞liter fraction of pooled plasma from 3-4 male mice of each genotype (Fig. 1) . The results were compared with those obtained from analysis of age-and sexmatched wild-type (Fig. 1 A) and apoE Ϫ͞Ϫ (Fig. 1C) mice. The lipoprotein profile of the Tg(apoB ϩ͞ϩ ) mice (Fig. 1B) was similar to that reported (12, 13) . As expected, the LDLR Ϫ͞Ϫ mice had an increase in the LDL-C peak and no change in the amount of HDL-C when compared with wild-type mice (Fig. 1 D vs. A) . Expression of human apoB-100 in the LDLR Ϫ͞Ϫ mice resulted in a dramatic increase in the LDL cholesterol content and a fall in the cholesterol in the HDL fraction (Fig. 1F) . The distribution of triglyceride tended to parallel that of the cholesterol in the LDLR Ϫ͞Ϫ ;Tg(apoB ϩ͞ϩ ) mice so that most of the triglyceride was in the LDL fraction, which is similar to chow-fed mice (12, 13) and rabbits (30) expressing a human apoB-100 transgene.
Expression of apo(a) in the LDLR Ϫ͞Ϫ (Fig. 1E) and LDLR Ϫ͞Ϫ ; Tg(apoB ϩ͞ϩ ) (Fig. 1G) mice did not significantly affect the FPLC lipid profiles, although both groups of Tg(apoa ϩ͞Ϫ ) mice had proportionally more triglyceride in the VLDL fraction, suggesting that apo(a) expression was associated with higher plasma levels of triglycerides. However, the mean plasma level of triglycerides in the entire sample of male LDLR Ϫ͞Ϫ ;Tg(apoa ϩ͞Ϫ ) mice actually was lower than in the LDLR Ϫ͞Ϫ mice (109 Ϯ 10 vs. 132 Ϯ 13 mg͞dl) ( Table 1) . To determine the distribution of apo(a) among the lipoproteins, immunoblot analysis of the FPLC fractions was performed with an anti-apo(a) antibody (data not shown). In the LDLR Ϫ͞Ϫ ; Tg(apoB ϩ͞ϩ );Tg(apoa ϩ͞Ϫ ) mice, almost all of the immunodetectable apo(a) was present in fractions 8-17, which corresponded to LDL-sized particles (Fig. 1) ; only a trace amount of apo(a) was detected in the VLDL fraction, and no apo(a) was found in the density Ͼ 1.215 g͞liter fraction. Finding apo(a) in the LDL fraction of LDLR Ϫ͞Ϫ ;Tg(apoB ϩ͞ϩ );Tg(apoa ϩ͞Ϫ ) mice was not surprising because apo(a) is disufide-linked with human apoB in mice expressing both transgenes (12, 13) . Similar immunoblot analysis from plasma of the LDLR Ϫ͞Ϫ ;Tg(apoa ϩ͞Ϫ ) mice demonstrated that almost all the apo(a) was in the LDL fractions, with trace amounts in the VLDL fractions (data not shown). Previously, we demonstrated that human apo(a) does not form a covalent attachment to mouse apoB (18) but that mouse apoB immunoprecipitates with apo(a) in the Tg(apoa ϩ͞Ϫ ) mice (31) . Taken together, these findings are consistent with apo(a) circulating noncovalently associated with mouse apoB particles in the FIG. 1. Venous plasma was pooled from 3-4 male mice of the indicated genotype, and lipoproteins were isolated by ultracentrifugation. The wild-type mice were age-and sex-matched C57BL͞6 mice. The top fraction (density Ͻ 1.215 g͞liter) was subjected to FPLC using a Superose 6 column (Sigma). Thirty-five fractions were collected, and plasma cholesterol and triglycerides were measured in each fraction as described in Materials and Methods. (18) (19) (20) (21) (22) suggests that apo(a) is cleared together with LDL by the LDLR in these mice.
Mice were sacrificed at 6 mo of age, and the entire aortas were pinned out flat and stained with Sudan IV to reveal neutral (sudanophilic) lipids. The distribution of sudanophilia in the aortas from representative male mice of each genotype is shown in Fig. 2 . The Tg(apoB ϩ͞ϩ ) mice had no detectable sudanophilia (data not shown). Only very small focal regions of sudanophilia were present in the aortas of the LDLR Ϫ͞Ϫ mice (Fig. 2 A) . Expression of apo(a) in LDLR Ϫ͞Ϫ mice was not associated with a significant change in the amount or distribution of sudanophilia (Fig. 2B) . In contrast, expression of human apoB-100 in an LDLR Ϫ͞Ϫ background was associated with a dramatic increase in sudanophilic area throughout the aorta and extending into the external iliac arteries (Fig. 2C) . Of particular interest is the presence of extensive and large lesions in the posterior segments of the aortas of LDLR Ϫ͞Ϫ mice expressing human apoB-100 ( Fig. 2 C and D) . No increase in sudanophilia was seen with coexpression of apo(a) (Fig. 2D) . In these analyses, the intensity of sudanophilic staining varies and is not a reliable indicator of the thickness of the lesions.
To compensate for size differences among murine aortas, the sudanophilia was expressed as a percentage of total aortic surface area (Fig. 3) . Less than 1% of the surface area was sudanophilic in the Tg(apoB Histochemical and immunocytochemical studies were performed in a subset of animals from each genotypic group. Tiny, superficial lesions associated with the valve roots were present in the aortas of the LDLR Ϫ͞Ϫ ;Tg(apoa ϩ͞Ϫ ) mice, and only trace amounts of apo(a) immunoreactivity were seen associated with these lipid accumulations as well as on the endothelial surface of the aorta. In contrast, multiple lipid-laden lesions with fibrous caps (that stained positive with an ␣-actin antibody) were present in the aortic roots of the LDLR Ϫ͞Ϫ ;Tg(apoB ϩ͞ϩ ) mice, whether or not they also expressed apo(a) (data not shown).
The distributions of apo(a) and human apoB immunoreactivity were compared in adjacent sections from the proximal aorta of an LDLR Ϫ͞Ϫ ;Tg(apoB ϩ͞ϩ );Tg(apoa ϩ͞Ϫ ) mouse (Fig. 4) . The luminal aspect of the lesion, as well as the core, stained intensely with anti-human apoB-100 antibody (red, Fig. 4 A and C) . The apo(a) immunoreactivity (dark blue, Fig. 4 B and D) 3 . Extent of sudanophilia in the aortas of Tg(apoB ϩ͞ϩ ), LDLR Ϫ͞Ϫ , LDLR;Tg(apoa ϩ͞Ϫ ), LDLR Ϫ͞Ϫ ;Tg(apoB ϩ͞ϩ ), and LDLR Ϫ͞Ϫ ;Tg(apoB ϩ͞ϩ );Tg (apoa ϩ͞Ϫ ) mice. Mice were weaned at Ϸ21 days and then fed a low fat chow diet until 6 mo of age. The mice were sacrificed and the percent Sudan IV staining of the total aortic surface area was determined as described in Materials and Methods.
apoB-100 staining but also extended into the tunica media. Whether apo(a) staining in the media is caused by local production of apo(a) or plasma apo(a) infiltrating into this region will require further study. No immunoreactive apo(a) was detected in the tunica media in the absence of an overlying atherosclerotic plaque in either the LDLR Ϫ͞Ϫ ;Tg(apoB 
DISCUSSION
In this paper, we show that high level expression of human apoB-100 in LDLR Ϫ͞Ϫ mice is associated with the development of complex and extensive atherosclerotic lesions involving Ϸ15-20% of the aortic intimal surface. Lesion development does not require consumption of a high fat, high cholesterol diet, as is necessary for atherosclerotic lesion formation in LDLR Ϫ͞Ϫ (11) and Tg(apoB ϩ͞ϩ ) (14, 15) mice. The LDLR Ϫ͞Ϫ ;Tg(apoB ϩ͞ϩ ) mice have dramatically elevated plasma levels of cholesterol and triglyceride, which are contained predominantly in the IDL͞LDL fraction, and markedly reduced plasma levels of HDL-C. Coexpression of apo(a) in the LDLR Ϫ͞Ϫ ;Tg(apoB ϩ͞ϩ ) mice is not associated with a significant increase in the amount of lipid staining of the intimal aortic surface.
The ''en-face'' method used to quantify lesions shows the surface distribution of the lesions as well as their total surface areas. Unlike earlier mouse atherosclerosis models in which the lesions predominate in the aortic root (3, 8) (Fig. 2) would have been missed completely if only the aortic root had been analyzed. A disadvantage of the en-face method is that it provides little information regarding the thickness of the lesions.
However, there appears to be a good correlation between the relative lesion areas determined using the en-face method and the so-called ''Paigen'' method in which multiple sections from the proximal aorta are analyzed (8, 32) .
Overall, there was a significant correlation between percent lesion area and the plasma levels of cholesterol, as was reported previously for other genetically modified mice (8 mice has been performed, aortas of chow-fed, 6-mo-old, apoE Ϫ͞Ϫ mice were analyzed previously in the same laboratory by using an identical methodology (8) ; the mean lesion area in the LDLR Ϫ͞Ϫ ; Tg(apoB ϩ͞ϩ ) mice was 4-to 5-fold greater than that found previously in apoE (Fig. 1) . The large amount of triglyceride in the IDL͞LDL fraction of these mice cannot be ascribed solely to the absence of either the LDLR or cholesterol ester transfer protein. Similar elevations in plasma LDL-triglyceride are present in mice and rabbits (8, 12, 13, 30 ) expressing a human apoB-100 transgene, both of which have normal LDLR function. Coexpression of cholesterol ester transfer protein in mice expressing a human apoB-100 transgene mice does not alter significantly the lipid composition of LDL (33) . The high levels of triglyceride-rich LDL in the plasma of these mice is most likely due to increased hepatic synthesis of apoB-containing lipoproteins stimulated by the overexpression of apoB. The absence of the LDLR may result in a larger proportion of newly synthesized lipoprotein particles being released into the plasma, and these particles may not be as accessible to lipolysis because of yet-to-be defined differences in their lipid or protein composition.
The LDLR
Ϫ͞Ϫ
;Tg(apoa ϩ͞Ϫ ) mice have Ϸ2-fold higher plasma levels of apo(a) and cholesterol than some Tg(apoa ϩ͞Ϫ ) mice shown previously to have a significant increase in aortic lesion area (19) (20) (21) . Despite these higher levels of apo(a), we found no association between the expression of apo(a) in the LDLR Ϫ͞Ϫ mice and the extent of sudanophilic lesions in the aorta. A possible explanation for the discrepancy between our results and those of some prior studies (19) (20) (21) is that different methodologies were used to quantify lesion burden. In the earlier studies, the mean lesion area was determined in a statistically relevant sample of sections from the aortic root. Because the Tg(apoa ϩ͞Ϫ ) mice have very small accumulations of lipids in their aortas (19) (20) (21) , it is possible that the en face method used in this study does not detect the small lesions associated with apo(a) expression.
The ) mice because the apo(a) in the ''triple threat'' mice circulates just as it does in humans, i.e., covalently attached to LDL. Apo(a) expression had no effect on percent lesion area in the LDLR Ϫ͞Ϫ ;Tg(apoB ϩ͞ϩ ) mice (Fig. 3) . It is possible that the very high plasma levels of LDL in these mice overwhelm any atherogenic effect of Lp(a), although in humans the combination of high plasma levels of LDL and Lp(a) appears to be particularly atherogenic (23) . It also is possible that the plasma levels of apo(a) in these mice are not high enough to see any independent effect of Lp(a). It is noteworthy, however that despite the presence of large amounts of immunodetectable apo(a) within the lesions of the LDLR Ϫ͞Ϫ ; Tg(apoB ϩ͞ϩ );Tg(apoa ϩ͞Ϫ ) mice, no obvious differences were found in the morphology of their vascular lesions when compared with the LDLR Ϫ͞Ϫ ;Tg(apoB ϩ͞ϩ ) mice. It has been proposed that apo(a) is atherogenic in the mouse because it interferes with plasminogen and TGF␤-1 activation (34, 35) . No thrombotic lesions were identified in the apo(a) and Lp(a) transgenic mice. Nor was any qualitative increase in smooth muscle proliferation appreciated in the subset of mice expressing apo(a) or Lp(a), although this needs to be analyzed in a more systematic quantitative fashion.
The most important observation in this study is that LDLR Ϫ͞Ϫ ; Tg(apoB ϩ͞ϩ ) mice, which have dramatically elevated plasma levels of IDL͞LDL and reduced HDL, develop large, complex atherosclerotic lesions on a chow diet within a useful experimental time frame. This mouse model provides an important alternative to the apoE Ϫ͞Ϫ mice for the study of atherosclerosis. The LDLR Ϫ͞Ϫ ; Tg(apoB ϩ͞ϩ ) mice develop much more extensive aortic lesions (Ϸ4 fold greater) and have an atherogenic lipoprotein profile that is more typical of that seen in humans than do the apoE Ϫ͞Ϫ mice, although the triglyceride content of the LDL is much higher than that seen in man. A disadvantage of using the LDLR Ϫ͞Ϫ ; Tg(apoB ϩ͞ϩ ) mice is the difficulty of introducing other gene modifications into the LDLR Ϫ͞Ϫ ;Tg(apoB ϩ͞ϩ ) background; additional crosses are required to achieve homozygosity at three loci. A possible strategy to obviate this problem would be to insert the human apoB-100 transgene into the mouse LDLR locus. Such a mouse would provide an even more powerful tool for the study of atherosclerosis.
